Skip to content

Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs

Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs: a Randomized, Double-Blinded, Placebo Controlled-Trial

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04901065
Acronym
Xylofuns
Enrollment
88
Registered
2021-05-25
Start date
2021-05-11
Completion date
2021-06-07
Last updated
2021-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

Since the beginning of the COVID-19 pandemic, nasopharyngeal swabs (NPS) have been recommended to detect the virus. This procedure has been reported to be painful by 85% of children The aim of the study was to assess whether pretreatment with topical lidocaine reduces the discomfort experienced by children during a nasopharyngeal swab. This was a RCT among children aged 8-17 years old who need a NPS. The primary outcome was pain intensity as measured by the Visual Analog Scale .

Interventions

The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle

DRUGPlacebo

The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery

Sponsors

Evelyne D.Trottier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The research assistant enrolling the patients was blinded to treatment assignment because he did not know to which bottle the patient was randomized (A or B) and he did not know what was contained in the bottle

Eligibility

Sex/Gender
ALL
Age
8 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

Inclusion: * 6-17 years old inclusively * Children for whom a NPS was ordered Exclusion: * Children presenting with the following acute conditions, which could either prevent the lidocaine from being properly administered, or pose a risk for the patient as increased absorption of the medication might occur: * Nasal or airway burns, trauma or major anomaly * Cardiorespiratory compromise * Children for whom an informed consent could not be obtained * Any other life-threatening condition or priority one patient requiring emergency support * Language barrier * Children presenting with conditions that could prevent their ability to reliably report their pain: * Severe intellectual disability * Severe pain upon presentation * Administration of opiates prior to the NPS * Children presenting with the following chronic conditions, which could either prevent the lidocaine from being properly administered, or pose a risk for the patient: * Hypersensitivity/allergy to the medication or a known component * Methemoglobinemia * G6PD deficiency * Familial malignant hyperthermia * Pseudocholinesterase deficiency * Severe hepatic impairment * Severe cardiac condition or use of antiarrhythmic medication * Risk of airway aspiration

Design outcomes

Primary

MeasureTime frameDescription
Pain during the procedureDuring procedureSelf-reported pain immediately after the NPS as measured using a validated self-reported pain scale: the Visual Analog Scale (VAS

Secondary

MeasureTime frameDescription
DiscomfortDuring procedureDiscomfort at administration of the study intervention using a yes/no question
Pain 2 NRSDuring procedureEvaluation of pain immediately after the NPS using a clinically relevant tool, the verbal Numeric Rating Scale
Number of patients with physical restrictionDuring procedureEvaluation of the patient position (sitting, lying down, standing) and if physical restraints was done (none, redirection of movements, comfort position/minimal comfortable restriction or actively restrain) to perform the swab and to which extent
Anxiety during the procedureDuring procedure● Evaluation of fear prior to the administration of the study intervention and the NPS using the Children's Fear Scale
Adverse event48 hours following interventionAdverse effects reported by caregivers in the 24-48hrs following administration of medication
Desire to reuse the intervention in a futur procedure, at follow up48 hours following interventionAsking caregivers in the 24-48hrs following intervention if they would recommend the intervention before a NPS as standard of care for pediatric patients. Yes/no question.
Utility according to nursesDuring procedure● Triage nurses evaluation on the efficiency of the intervention in reducing pain in the patient, using a likert scale of 1 to 5

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026